Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.11 USD
Change Today +0.06 / 0.99%
Volume 248.6K
NEO On Other Exchanges
Symbol
Exchange
Berlin
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

neogenomics inc (NEO) Snapshot

Open
$6.03
Previous Close
$6.05
Day High
$6.19
Day Low
$6.03
52 Week High
07/10/15 - $6.85
52 Week Low
01/22/15 - $3.33
Market Cap
369.7M
Average Volume 10 Days
385.8K
EPS TTM
$0.01
Shares Outstanding
60.5M
EX-Date
--
P/E TM
549.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for NEOGENOMICS INC (NEO)

Related News

No related news articles were found.

neogenomics inc (NEO) Related Businessweek News

No Related Businessweek News Found

neogenomics inc (NEO) Details

NeoGenomics, Inc., together with its subsidiary, NeoGenomics Laboratories, Inc., operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company performs analyses for hematopoietic cancers, such as leukemia and lymphoma; and solid tumor cancers comprising breast, lung, colon, and bladder cancer. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry testing services to localize proteins in cells of a tissue section; and molecular testing services that focus on the analysis of DNA and RNA, as well as on the structure and function of genes at the molecular level. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

440 Employees
Last Reported Date: 04/30/15
Founded in 2001

neogenomics inc (NEO) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $735.3K
Chief Financial Officer
Total Annual Compensation: $344.0K
Chief Operating Officer
Total Annual Compensation: $88.8K
Chief Compliance Officer, Executive Vice Pres...
Total Annual Compensation: $177.5K
Chief Medical Officer and Director of Researc...
Total Annual Compensation: $131.0K
Compensation as of Fiscal Year 2014.

neogenomics inc (NEO) Key Developments

NeoGenomics, Inc. Launches Germline Cancer Predisposition Testing Services

NeoGenomics Inc., has launched a new line of germline cancer predisposition testing services. The new tests include comprehensive testing for BRCA1 and BRCA2 encompassing an analysis of all exons and adjacent intronic regions. The testing encompasses point mutations, indels (small insertions/deletions), and large deletions and insertions. In addition, the company is launching a 73 multigene panel for testing patients with a strong family history of inherited cancer, but who have no evidence of BRCA1 or BRCA2 mutation. The new BRCA1 and BRCA2 testing has also been integrated into new cancer profile tests for breast, ovarian and pancreatic cancer. In addition to testing patients with cancer, these tests may be used to screen patients to determine if they carry these mutations. Carriers of BRCA1 or BRCA2 mutations have higher incidence of contralateral breast cancer, ovarian cancer, pancreatic cancer, male breast cancer, fallopian tube cancer, peritoneal tumor, prostate cancer, and melanoma. This testing provides important information not only for long term management of patients, but also for determining appropriate treatments using recently approved therapies. The company also announced that it has launched germline testing for Lynch Syndrome, also known as Hereditary Non-Polyposis Colorectal Cancer (HNPCC). This testing includes comprehensive analysis for point mutations, indels, and large deletions/insertions in MLH1, MSH2, EPCAM, MSH6, and PMS2 genes. This offering complements the company's HNPCC screening using immunohistochemistry (IHC) and molecular tests, and is recommended as a reflex. Multiple tumors are related to Lynch syndrome including tumors of the stomach, small intestine, endometrium, ovary, genitourinary tract, sebaceous skin, and brain.

Neogenomics Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Reiterates Earnings Guidance for the Second Half of 2015 and Revenue Guidance for the Full Year of 2015

Neogenomics Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company’s net revenue was $24,370,000 against $20,670,000 a year ago. Income from operations was $28,000 against $578,000 a year ago. Loss before taxes was $161,000 against income before taxes of $325,000 a year ago. Net loss was $176,000 or $0.00 basic and diluted per share against net income of $274,000 or $0.01 basic and diluted per share a year ago. EBITDA was $1,788,000 against $1,885,000 a year ago. Adjusted EBITDA (non-GAAP) was $2,407,000 against $2,082,000 a year ago. For the six months, the company’s net revenue was $47,396,000 against $38,852,000 a year ago. Loss from operations was $534,000 against income from operations $972,000 a year ago. Loss before taxes was $918,000 against income before taxes of $454,000 a year ago. Net loss was $937,000 or $0.02 basic and diluted per share against net income of $376,000 or $0.01 basic and diluted per share a year ago. EBITDA was $2,905,000 against $3,486,000 a year ago. Adjusted EBITDA (non-GAAP) was $3,925,000 against $3,767,000 a year ago. Net cash provided by operating activities was $1,897,000 against $5,298,000 a year ago. The company also announced that it was lowering its previously issued revenue guidance for the full year 2015 to $100 million - $103 million against the previous guidance of $103 million – $108 million.  The company reiterated its expectation of a return to profitability in the second half of 2015.

NeoGenomics, Inc. Expands Multimodality Cancer Profile Testing

NeoGenomics Inc. announced an expansion of its comprehensive multimodality NeoTYPE™ tumor-type specific cancer profiling tests to include new profiles for head and neck tumors, pancreatic cancer, liver cancer, sarcoma, and for cancers of unknown primary (CUP). These new tests integrate a variety of technologies, including next generation sequencing, viral in-situ hybridization, FISH, and immunohistochemistry. A number of new tests are being added to NeoGenomics cancer diagnostic test menu. HPV testing is being integrated with next generation sequencing (NGS) for head and neck cancer. A complete analysis of somatic mutations in BRCA1 and BRCA2 are now part of breast, ovarian and pancreatic cancer profiling to aid in selecting recently approved therapy for cancers with impaired DNA repair mechanism. Additionally, all profiles now include analysis of PD-L1 expression by immunohistochemistry. In addition, NeoGenomics is offering complete profiling for cancers of unknown primary. This profiling incorporates analysis using extensive immunohistochemistry, Next Generation Sequencing of 315 genes and 9 FISH probes. This comprehensive profiling of CUP provides information to help identify not only the potential origin of the tumor but, more importantly, provide information that helps in selecting therapy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEO:US $6.11 USD +0.06

NEO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cancer Genetics Inc $10.67 USD -0.08
Enzo Biochem Inc $3.00 USD -0.02
Foundation Medicine Inc $20.30 USD -2.00
Psychemedics Corp $12.02 USD +0.12
Response Genetics Inc $0.12 USD +0.0019
View Industry Companies
 

Industry Analysis

NEO

Industry Average

Valuation NEO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.9x
Price/Book 6.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOGENOMICS INC, please visit www.neogenomics.org. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.